We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Drug Development in Microgravity Research Conducted Aboard Atlantis' Last Mission

By LabMedica International staff writers
Posted on 23 Jun 2010
Space Shuttle Atlantis returned from the International Space Station (ISS), landing at the Kennedy Space Center (Houston, TX, USA) May 26, 2010, with the 10th scientific payload for a commercial biotech company conducting drug development research.

Astrogenetix (Austin, TX, USA), is conducting research on methicillin-resistant Staphylococcus aureus (MRSA) as part of the ISS [U.S.] National Laboratory Pathfinder Vaccine (NLP-V) missions. More...
"By removing a force as fundamental as gravity in the course of this research, we're witnessing bacteria grow in ways that have not been demonstrated on Earth,” said John Porter, chief executive officer of Astrogenetix. "The use of microgravity as a new research platform will bring meaningful advancements in drug discovery and development, and we believe this early vaccine work is just the beginning.”

The company is utilizing the unique conditions of microgravity to reveal changes in bacteria, which can be targeted to create new vaccines and therapeutics. Astrogenetix has identified target genes for MRSA virulence by growing the bacteria in the microgravity environment during previous NLP-V. The company is conducting controls on this flight to validate earlier research by sending up several different strains of the bacteria, which were genetically modified to remove target genes that are believed to be associated with virulence of this organism. Moreover, the company is bringing back live forms of the bacteria that were grown in microgravity to compare to ground-based samples of the bacteria. The scientists will perform postflight analysis on the microbes to evaluate the changes that occurred on this mission.

"Each flight opportunity allows us to learn more about the bacteria and the changes that are occurring as they grow in space,” added Dr. Jeanne Becker, chief science officer for Astrogenetix. "The knowledge we're gaining can be applied to streamline and accelerate the development of vaccines and therapeutics on Earth.”

MRSA is a type of bacteria that is not responsive to commonly used antibiotics. In the United States alone, MRSA is responsible for 100,000 cases of severe infections and more than 19,000 deaths yearly. In the past 10 years, infection and mortality due to this organism has increased significantly, exceeding the death rate for HIV.

A subsidiary of Astrotech Corp., Astrogenetix, Inc. is a biotechnology company formed to commercialize biotechnology products processed in the unique environment of microgravity.

Related Links:

Autogenetix
International Space Station National Laboratory Pathfinder Vaccine



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Aspiration System
VACUSAFE
New
Microbiology Laboratory Automation Solution
BD Kiestra™ ReadA+BarcodA
Pipette Calibration System
Artel PCS®
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Researchers developed three mathematical biomarkers from routine PSA blood tests that may help predict early prostate cancer treatment outcomes and personalize adaptive therapy (Image Credit: Adobe Stock)

Mathematical Biomarkers Use Routine Blood Tests to Guide Adaptive Prostate Cancer Therapy

Personalizing systemic therapy for prostate cancer remains challenging because tumors can evolve under treatment pressure, driving resistance and early relapse. Continuous high-dose regimens may initially... Read more

Molecular Diagnostics

view channel
Image: The duet mosaic family comprises duet +modC mosaic and duet 6-base mosaic, two cfDNA-optimized multiomic sequencing workflows for liquid biopsy and translational research. (Photo courtesy of bimodal)

New Liquid Biopsy Workflow Maximizes Tumor Signals from Limited Blood Samples

Liquid biopsy seeks to detect tumor-derived signals from small blood samples, but circulating cell-free DNA is scarce and heterogeneous, limiting sensitivity. Combining complementary signals such as methylation,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.